低强度超声联合托泊替康诱导人肝癌细胞凋亡的研究

目的: 研究低强度超声联合托泊替康诱导人肝癌细胞(HepG2)凋亡的协同效应以及相关的机制。方法: 应用HepG2,实验分为托泊替康处理组、超声处理组、联合治疗组(托泊替康+超声),评估细胞生存活力、细胞凋亡,胞内托泊替康累积及空化效应。结果: 当超声强度为 0.8 W/cm² 及以上时,协同托泊替康能明显诱导HepG2细胞凋亡,1.0 W/cm² 超声辐照联合托泊替康时细胞凋亡率为 12.88%,空化效应在凋亡诱导实验中促进了托泊替康胞内渗入,增加胞内积累。结论: 联合低强度超声能增强托泊替康的凋亡诱导效应,空化效应是其协同增强的主要机制。     

Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport

A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan (TPT) has been extended from a previously published model. The extended model describes the drug activity and delivery of the pharmacologically active form to the DNA target as well as the catalysis of the aldehyde dehydrogenase (ALDH) enzyme and the elimination of drug from the cytoplasm via the efflux pump. Verification of the proposed model is achieved using scanning-laser microscopy data from live human breast cancer cells. Before estimating the unknown model parameters from the experimental in vitro data it is essential to determine parameter uniqueness (or otherwise) from this imposed output structure. This is formally performed as a structural identifiability analysis, which demonstrates that all of the unknown model parameters are uniquely determined by the output structure corresponding to the experiment.